59 citations,
August 2021 in “Frontiers in Endocrinology” GLP-1 receptor agonists, like Dulaglutide, Liraglutide, and Semaglutide, have potential benefits beyond the pancreas, including neuroprotection, pain suppression, cardiovascular protection, obesity management, and cancer treatment, but there are concerns about pancreatitis and pancreatic cancer risks.
August 2024 in “Nutrition Bulletin” GLP-1 receptor agonists help with weight loss but need to be combined with other treatments for best results.
May 2024 in “Psychiatric News” Weight-loss drugs are not linked to suicidal thoughts.
11 citations,
December 2022 in “Arterial Hypertension” New guidelines stress early diagnosis and lifestyle changes to manage metabolic syndrome and prevent complications.
4 citations,
January 2019 in “Therapeutic Advances in Endocrinology and Metabolism” Medications for PCOS don't seem to raise heart disease risk.